Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of “Buy” by Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received an average rating of “Buy” from the seven analysts that are covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $92.17.

A number of research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Oppenheimer initiated coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. Finally, Truist Financial restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently modified their holdings of KROS. China Universal Asset Management Co. Ltd. increased its stake in Keros Therapeutics by 356.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after purchasing an additional 2,702 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. Arizona State Retirement System acquired a new stake in shares of Keros Therapeutics during the fourth quarter valued at approximately $231,000. Bayesian Capital Management LP purchased a new stake in shares of Keros Therapeutics in the 1st quarter valued at approximately $267,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Keros Therapeutics by 117.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after purchasing an additional 2,822 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $50.29 on Friday. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -9.77 and a beta of 1.23. Keros Therapeutics has a 1 year low of $27.02 and a 1 year high of $73.00. The business has a fifty day moving average of $47.35 and a 200-day moving average of $55.38.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.12. The company had revenue of $0.08 million during the quarter. During the same period in the previous year, the company earned ($1.26) EPS. The firm’s quarterly revenue was down 97.3% compared to the same quarter last year. On average, equities research analysts predict that Keros Therapeutics will post -4.8 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.